10-Q quarterly report · filed Nov 5, 2026

Aclaris Therapeutics, Inc. (ACRS) Q3 2026 10-Q Quarterly Report

Short answer

Aclaris Therapeutics, Inc. (ACRS) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $1M (down 55.1% year over year) with net income of −$19M.

Q3 2026 key financials · XBRL

Revenue
$1M
−55.1% YoY · −9.1% QoQ
Net income
−$19M
−26.7% YoY · +13.9% QoQ
Operating margin
-1441.2%
EPS (diluted)
−$0.13
−8.3% YoY · +13.3% QoQ

Source: XBRL data from the Aclaris Therapeutics, Inc. (ACRS) Q3 2026 10-Q on SEC EDGAR. USD.

Aclaris Therapeutics, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Q3 revenue $1.481M, down $1.818M YoY from $3.299M, primarily lower licensing revenue
  • Q3 net loss $18.510M vs $14.614M YoY, operating loss $21.344M vs $17.149M
  • Strongest R&D growth: ATI-052 expense $5.906M, up $4.069M YoY; ATI-9494 $4.676M, up $3.272M
  • Cash and securities $204.6M, including $20.4M cash and $184.2M marketable securities
  • Nine-month operating cash use $62.076M vs $33.982M; management expects losses and additional capital needs near term

Risk Factors

  • Liquidity risk: $204.6 million cash, cash equivalents and marketable securities against $59.8 million nine-month net loss
  • Financing risk: October offering added $46.7 million net proceeds through 7,785,714 shares and 6,500,000 pre-funded warrants
  • Marketable-securities concentration: $184.2 million fair value, including $70.5 million corporate debt securities maturing within one to three years
  • Regulatory milestone exposure: $10.7 million contingent consideration tied to Confluence regulatory and commercial milestones

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Aclaris Therapeutics, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.